Patent ID: 11858999
Assignee: AMGEN K-A, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method of treating scleroderma in a human patient in need thereof, which method comprises administering to the patient an effective amount of human monoclonal antibody, or an antigen-binding fragment thereof, that specifically binds the human IL-17 receptor A, wherein the human monoclonal antibody comprises:
(a) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 146, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 147, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 148, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 224, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 225, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 226; or
(b) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 14 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 40,
whereby the human monoclonal antibody specifically binds to human IL-17 receptor A and inhibits the binding of IL-17A to IL-17 receptor A, and the scleroderma is treated in the human patient.